EUVIMEDEUVIMED entdecken
Multizentrische Studie

Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction

Glucagon‐Like Peptide‐1-Rezeptoragonisten bei adipöser Herzinsuffizienz mit erhaltener Ejektionsfraktion

Padmini Selvaganesan iD, Mohamad Karnib, Irfan Helmy iD, Rosita Zakeri iD, Yusef Babar Saeed iD, Jayakumar Sahadevan iD, Mohammed Najeeb Osman iD, Anirban Mondal, Sherry Milfred-LaForest iD, James C Fang iD, Yogesh N V Reddy iD, Varun Sundaram iD

Journal of the American Heart Association · 03.11.2026 · 15 (21)

DOI: 10.1161/jaha.126.050387 ↗

Auf einen Blick

Bei Patient:innen mit Adipositas, Typ-2-Diabetes und Herzinsuffizienz mit erhaltener Ejektionsfraktion war der Beginn einer GLP-1RA mit einem geringeren Risiko für Tod oder Hospitalisierung wegen Herzinsuffizienz verbunden.

Fragestellung

Sind GLP-1-Rezeptoragonisten im Vergleich zu DPP4-Inhibitoren oder Sulfonylharnstoffen bei dieser Patient:innengruppe mit weniger Gesamtmortalität oder Herzinsuffizienz-Hospitalisierungen assoziiert?

Methode

Nationweite multizentrische Kohortenstudie mit new-user- und active-comparator-Design im Veterans Affairs Health System; inverse probability of treatment weighting nach Propensity Score.

Ergebnisse

1024 GLP-1RA-Anwender:innen und 796 DPP4-Inhibitor-/Sulfonylharnstoff-Anwender:innen. Für den primären Endpunkt ergab sich eine geringere Rate unter GLP-1RAs: adjustierte Hazard Ratio 0,78 (95 %-KI 0,64–0,95), P =0.01.

Schlussfolgerung der Autor:innen

Bei Patient:innen mit adipöser Herzinsuffizienz mit erhaltener Ejektionsfraktion und Typ-2-Diabetes war der Beginn einer GLP-1RA mit einer geringeren Inzidenz von Tod oder Herzinsuffizienz-Hospitalisierung verbunden.

Kernaussagen

  • Primärer Endpunkt: geringeres Risiko unter GLP-1RAs
  • adjustierte Hazard Ratio 0,78 (95 %-KI 0,64–0,95)
  • Gewichtsverlust war unter GLP-1RAs etwas stärker

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Padmini Selvaganesan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Case Western Reserve University School of Medicine Cleveland OH USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Diabetes Mellitus, Type 2, Obesity. Die Arbeit nennt 28 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction.

Methods

PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m 2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics.

Results

Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P =0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%).

Conclusions

Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeDiabetes Mellitus, Type 2ObesityGlucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHumansMaleFemaleAgedUnited StatesSulfonylurea CompoundsMiddle AgedHospitalizationHypoglycemic Agents

Stichwörter der Autor:innen

cardiovascular outcomesheart failure hospitalizationsheart failure with preserved ejection fractionobesityreal‐world evidence

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsSulfonylurea CompoundsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medicine Case Western Reserve University School of Medicine Cleveland OH USA.
  • Department of Cardiology Louis Stokes Cleveland Veterans Affairs Medical Center Cleveland OH USA.
  • School of Cardiovascular Medicine & Sciences, James Black Centre King's College London London UK.
  • Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center Cleveland OH USA.
  • Geriatric Research, Education and Clinical Center (GRECC), Louis Stokes Cleveland VA Medical Center Cleveland OH USA.
  • Department of Mathematics, Applied Mathematics, and Statistics Case Western Reserve University Cleveland OH USA.

ORCID-Profile: Padmini Selvaganesan, Irfan Helmy, Rosita Zakeri, Yusef Babar Saeed, Jayakumar Sahadevan, Mohammed Najeeb Osman, Sherry Milfred-LaForest, James C Fang, Yogesh N V Reddy, Varun Sundaram

Zitieren

APA

Selvaganesan, P., Karnib, M., Helmy, I., Zakeri, R., Saeed, Y. B., Sahadevan, J., Osman, M. N., Mondal, A., Milfred-LaForest, S., Fang, J. C., Reddy, Y. N. V., & Sundaram, V. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.126.050387

Vancouver

Selvaganesan P, Karnib M, Helmy I, Zakeri R, Saeed YB, Sahadevan J, et al. Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.126.050387

BibTeX
@article{Selvaganesan2026,
  author = {Selvaganesan, Padmini and Karnib, Mohamad and Helmy, Irfan and Zakeri, Rosita and Saeed, Yusef Babar and Sahadevan, Jayakumar and Osman, Mohammed Najeeb and Mondal, Anirban and Milfred-LaForest, Sherry and Fang, James C and Reddy, Yogesh N V and Sundaram, Varun},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {21},
  doi = {10.1161/jaha.126.050387}
}
Kostenlos starten →